Germline deletions in the tumour suppressor gene FOCAD are associated with polyposis and colorectal cancer development by Weren, R.D.A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/155369
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Journal of Pathology
J Pathol 2015; 236: 155–164
Published online 26 March 2015 in Wiley Online Library
(wileyonlinelibrary.com) DOI: 10.1002/path.4520
ORIGINAL PAPER
Germline deletions in the tumour suppressor gene FOCAD are
associated with polyposis and colorectal cancer development
Robbert DA Weren,1 Ramprasath Venkatachalam,1 Jean-Baptiste Cazier,2 Henner F Farin,3 C Marleen Kets,1
Richarda M de Voer,1 Lilian Vreede,1 Eugène TP Verwiel,1 Monique van Asseldonk,4 Eveline J Kamping,1
Lambertus A Kiemeney,5 Kornelia Neveling,1 Katja KH Aben,5,6 Luis Carvajal-Carmona,7 Iris D Nagtegaal,4
Hans K Schackert,8 Hans Clevers,3 Marc van de Wetering,3 Ian P Tomlinson,2 Marjolijn JL Ligtenberg,1,4
Nicoline Hoogerbrugge,1 Ad Geurts van Kessel1 and Roland P Kuiper1*
1 Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands
2 Wellcome Trust Centre for Human Genetics University of Oxford, UK
3 Hubrecht Institute, University Medical Centre Utrecht, The Netherlands
4 Department of Pathology, Radboud university medical center, Nijmegen, The Netherlands
5 Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands
6 Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands
7 Genome Center and Department of Biochemistry and Molecular Medicine, School of Medicine, University of California at Davis, CA, USA
8 Department of Surgical Research, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Germany
*Correspondence to: RP Kuiper, Department of Human Genetics, Radboud university medical center, PO Box 9101, 6500 HB Nijmegen,
The Netherlands. E-mail: Roland.Kuiper@radboudumc.nl
Abstract
Heritable genetic variants can significantly affect the lifetime risk of developing cancer, including polyposis and
colorectal cancer (CRC). Variants in genes currently known to be associated with a high risk for polyposis or
CRC, however, explain only a limited number of hereditary cases. The identification of additional genetic causes
is, therefore, crucial to improve CRC prevention, detection and treatment. We have performed genome-wide and
targeted DNA copy number profiling and resequencing in early-onset and familial polyposis/CRC patients, and
show that deletions affecting the open reading frame of the tumour suppressor gene FOCAD are recurrent and
significantly enriched in CRC patients compared with unaffected controls. All patients carrying FOCAD deletions
exhibited a personal or family history of polyposis. RNA in situ hybridization revealed FOCAD expression in epithelial
cells in the colonic crypt, the site of tumour initiation, as well as in colonic tumours and organoids. Our data suggest
that monoallelic germline deletions in the tumour suppressor gene FOCAD underlie moderate genetic predisposition
to the development of polyposis and CRC.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Adenomatous polyposis, the development of numerous
polyps in the colon and rectum, is strongly associated
with the prevalence of heritable genomic variants.
These polyps have been shown to act as precursors of
in situ carcinomas. Therefore, individuals who develop
adenomatous polyposis are considered to be at an
increased risk to develop colorectal cancer (CRC) [1],
the second most frequent cause of cancer-related death
in the Western world. In the past, several genes have
been associated with a high risk for polyposis, including
APC, MUTYH, AXIN2, SMAD4, BMPR1A, STK11,
POLD1 and POLE [2]. Although germline mutations
in these genes underlie the majority of polyposis cases,
approximately 20% of the cases remain unexplained
[3,4]. The identification of additional heritable genomic
variants will be instrumental for increasing our under-
standing of the molecular mechanisms underlying
polyposis and CRC initiation. This, in turn, will lead
to an improved clinical management of individuals and
families at risk, including surgical removal of polyps at
regular intervals during surveillance [5].
It is generally accepted that aberrant proliferation of
epithelial cells in colonic crypts represents an initiat-
ing step in the development of polyposis and CRC,
and it has been shown convincingly that so-called
crypt base columnar (CBC) and +4 cells, both consid-
ered to be crypt stem cells, possess cancer-initiating
potential [6–8]. Due to this potential, normal intestinal
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proliferation of these epithelial cells requires strict reg-
ulation. Loss of this strict regulation may underlie the
development of multiple polyps in the colon, as illus-
trated by familial adenomatous polyposis (FAP), juve-
nile polyposis syndrome (JPS) and hereditary mixed
polyposis syndrome (HMPS) [9]. FAP is caused by loss
of functional expression of APC, a negative regulator
of β-catenin, which results in increased activation of the
WNT signalling pathway and transcriptional activation
of proliferation-enhancing genes, including MYC and
CCND1 [10–12]. JPS and HMPS are both caused by
decreased activation of the TGFβ signalling pathway,
due to loss of functional expression of the cytoplasmic
mediator gene SMAD4 and the serine-threonine kinase
type I receptor gene BMPR1A [13,14]. Deregulation of
both the WNT and the TGFβ signalling pathways is
known to be associated with aberrant proliferation of
epithelial cells in the colonic crypt. The proliferation
of these cells is regulated by genes expressed in stem
cell progenitor cells [15]. These latter genes may, there-
fore, act as potential polyposis or CRC susceptibility
genes.
In the search for novel CRC susceptibility genes in
unexplained CRC families, we previously screened a
cohort of 41 early-onset CRC subjects with a clear posi-
tive family history of CRC for the presence of rare DNA
copy number variants (CNVs). This screening effort
revealed several germline CNVs in genes that are con-
sidered to be candidates for CRC susceptibility, such
as PTPRJ and GREM1 [16,17]. PTPRJ was previously
identified as a CRC susceptibility gene in mice [18]
and loss of heterozygosity (LOH) of PTPRJ has fre-
quently been observed in early stages of colorectal can-
cer development [19]. Genome-wide association stud-
ies (GWAS) have revealed thatGREM1-related germline
variants are associated with CRC susceptibility [20,21].
In addition, it has been found that a 40 kb germline dupli-
cation upstream of the GREM1 locus is associated with
an increased expression of GREM1. This duplication
was found to be recurrent in hereditary mixed polypo-
sis patients of Ashkenazi descent [22]. These examples
clearly illustrate the power of CNV screening in the
identification of novel heritable genomic variants affect-
ing the risk of developing polyposis/CRC.
Here, we show that the tumour suppressor gene
FOCAD [23] (encoding Focadhesin; previously known
as KIAA1797), located on 9p21.3, is recurrently affected
by CNVs in early-onset/familial CRC index patients
with a personal or family history of polyposis. Previous
studies have suggested a relatively low overall expres-
sion of FOCAD in the colon compared with other tissues
[23]. We show that FOCAD is abundantly expressed
in epithelial cells within the colonic crypt and that,
as such, this gene may play a role in the develop-
ment of polyposis and/or CRC. The variable numbers
of FOCAD-expressing cells in colonic organoids and
tumours from different patients suggest a role of this
gene in at least a subset of colonic tumours. Our find-
ings indicate that intragenic deletions in FOCAD are a
novel risk factor for polyposis and CRC development.
Materials and methods
Patient and control cohorts
Our initial discovery cohort, encompassing 41 patients
with microsatellite-stable (MSS) early-onset or familial
CRC, has been described previously [16]. For a sub-
sequent targeted screening of the FOCAD locus, we
used an independent validation cohort of 1232 patients
diagnosed with early-onset and/or familial CRC from
the Radboud University Medical Centre, Nijmegen, The
Netherlands (n= 89), from the Universitätsklinikum
Carl Gustav Carus, Dresden, Germany (n= 159) and
from the Wellcome Trust Centre for Human Genetics,
University of Oxford, UK (n= 984). An additional unre-
lated validation cohort of 38 polyposis patients from
The Netherlands, who were diagnosed with at least
10 polyps and (a) developed serrated adenomas, (b)
developed CRC, or (c) had a positive familial history of
polyposis, was also included. In order to exclude com-
mon copy number polymorphisms, we compared the
patient-derived data with CNVs reported in the Database
of Genomic Variants (http://projects.tcag.ca/variation)
[24], our in-house database of copy number variants
obtained from healthy individuals in The Netherlands
(n= 1604), another control cohort encompassing 1880
individuals from the Nijmegen Biomedical Study [25]
and our in-house database of genomic variants, Genome
Diagnostics, department of Human Genetics, Nijmegen
(n= 9000). To determine the frequency of (highly con-
served) single-nucleotide variants (SNVs) in FOCAD
in subjects without a known history of polyposis/CRC,
exome data from the Exome Variant Server (EVS;
n= 6500) [26] and our in-house exome sequencing
database (MDI; n= 2096) were retrieved. An overview
of all cohorts, including the selection criteria and
genomic screening techniques used, is provided in
Table S1 (see supplementary material). All patient and
control samples were obtained after informed consent.
Multiplex Ligation-dependent Probe Amplification
(MLPA) and genomic qPCR
MLPA probes were designed for the FOCAD/miR-491
locus according to guidelines provided by
MRC–Holland (Amsterdam, The Netherlands) and,
subsequently, MLPA assays were performed and anal-
ysed as described previously [16]. Genomic qPCR
was performed on a 7500 Fast Real-Time PCR sys-
tem (Applied Biosystems, Foster City, CA, USA), as
described previously [16], using SYBR Green-based
quantification according to the manufacturer’s protocol
(Bio-Rad, Veenendaal, The Netherlands). Both MLPA
and genomic qPCR primers are available upon request.
Real-time quantitative RT–PCR
Real-time quantitative reverse-transcriptase PCR
(RT–PCR) was performed as described previously
[27]. Briefly, cDNA was prepared from 1–2 μg RNA
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through RT–PCR with Oligo(dT) and random primers,
using a RNA LA PCR kit (AMV; Takara Bio Inc.,
Shiga, Japan). Real-time quantification was performed
on a 7500 Fast Real-Time PCR system (Applied
Biosystems), using SYBR Green-based quantification
(Applied Biosystems). All experiments were performed
at least in duplicate and data were normalized using the
housekeeping gene HPRT (primer sequences available
upon request).
Targeted resequencing
Amplification of the 43 coding exons of FOCAD of
a selected number of samples of our extended cohort
from The Netherlands and Germany (n= 117 of 248
samples) as well as polyposis patients from the Nether-
lands (n= 33 of 38 samples) (see above) was performed
using an Access Array IFC system (Fluidigm; primer
sequences available upon request) and the amplified
fragments were used subsequently for library prepara-
tion and massive parallel sequencing. Sequencing of
the 117 selected cohort samples and the 33 polypo-
sis patient samples was performed using a 454 GS
FLX sequencer (Roche) with Titanium series reagents
and an IonTorrent semiconductor sequencer (Life Tech-
nologies), respectively. Data analyses were performed
using the Seqnext (JSI Medical Systems GmbH) and
NextGENe software packages (Softgenetics), respec-
tively. The average depths of coverage/amplicon are
provided in Figures S1 and S2 (see supplementary
material). In silico pathogenicity predictions were per-
formed using an in-house data analysis pipeline [28],
PolyPhen 2.0 (http://genetics.bwh.harvard.edu/pph2/),
SIFT, Align GVGD and phyloP (Alamut v 2.1; Inter-
active Biosoftware, Rouen, France). Non-synonymous
SNVs present in dbSNP, in our in-house exome database
and/or in the EVS were considered non-damaging poly-
morphisms and, therefore, excluded from our analyses.
Sanger sequencing was performed to confirm novel vari-
ants that fulfilled our a priori quality settings (see sup-
plementary material, Table S2).
Colonic organoids
Human colonic organoids and tumouroids were obtained
and cultured as described previously [29]. Briefly,
colonic samples were collected during endoscopies and,
after crypt/adenoma isolation, cultured using previously
described conditions [30].
RNA in situ hybridization
RNA in situ hybridization (ISH) analyses were
performed as described previously [31]. Briefly,
digoxigenin-labelled RNA probes were generated
using IMAGE clone 1204456 as a template (Source
BioScience). Both healthy and neoplastic colonic
tissues were fixed, embedded in paraffin and pre-
treated prior to hybridization. After hybridization, the
detection of signals was performed using an alkaline
phosphatase-coupled anti-digoxigenin antibody.
Statistics
A one-sided χ2 test with Yates’ correction was applied
to determine the statistical significance of enrichment
of FOCAD deletions in CRC patients compared to the
control groups. Statistical significance of the RT–PCR
results was determined using a two-tailed t-test, assum-
ing equal variances. For both tests, the predetermined
level of significance was p= 0.05.
Results
FOCAD deletions are recurrent in familial
and early-onset CRC patients
In a previous microarray-based CNV screen of famil-
ial and early-onset microsatellite-stable (MSS) CRC
patients (n= 41), we identified an intragenic deletion
affecting the FOCAD gene locus, which encodes the
potential tumour suppressor Focadhesin and miRNA
miR-491, in one of the index patients (patient A) [16]. In
order to assess whether an association of FOCAD dele-
tions with CRC development could be confirmed, we
screened an additional cohort of familial and early-onset
CRC patients (n= 1232) as well as healthy controls
(n= 1880), using targeted MLPA analysis. This screen
revealed two additional FOCAD deletions in the CRC
patient cohort (patients B and C), but none in the healthy
control cohort (Figure 1). In addition, no FOCAD dele-
tions were found to be reported in our in-house database
of copy number variants obtained from healthy indi-
viduals in The Netherlands (n= 1604), whereas only
a single intragenic FOCAD deletion was identified in
the samples run by our array diagnostics pipeline at the
department of Human Genetics, Nijmegen (n= 9000).
Therefore, the enrichment of FOCAD deletions in CRC
patients (2/1232) compared to the control group (1/12
400) is significant (p= 0.0067). Together, these results
indicate that deletions in FOCAD are rare but recurrent
in familial and early-onset CRC patients.
The open reading frame is affected in all patients
with FOCAD deletions
To determine the genetic boundaries of the FOCAD
deletions, we mapped the deletion breakpoints in each
of the three patients, using a combined MLPA and
genomic qPCR-based approach. All three deletions were
found to be different in size and location, encompass-
ing exons 4–23 in patient A, 2–14 in patient B and
7–20 in patient C (Figure 2). Therefore, the miR-491
locus, located within intron 4 of the FOCAD gene, was
only affected in patients A and B. All three deletions
do affect the FOCAD gene: two deletions include exon
4, containing the ATG start site (patients A and B),
whereas the deletion in patient C results in a frameshift
in the coding sequence and, consequently, a premature
translational stop. As a consequence, all identified dele-
tions encompass several exons and disturb the open
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Figure 1. Confirmation and identification of genomic deletions in the FOCAD gene: confirmation of the genomic deletion by MLPA in
germline DNA of patient A (index patient) and identification of genomic FOCAD deletions by MLPA in the germline of patients B and C
(extended cohort); three controls were included in the MLPA assay; ex, exon
reading frame (ORF) of FOCAD, strongly suggesting a
loss-of-function scenario.
Truncating second-hit mutations are not detected
in polyps and tumours of FOCAD deletion carriers
Based on Knudson’s two-hit paradigm, we questioned
whether loss of the remaining wild-type allele might
be a common event in the development of polyps
and tumours in FOCAD deletion carriers. Therefore,
Sanger sequencing was performed to reveal the pres-
ence of truncating somatic second-hit mutations in avail-
able tumour tissues of two index patients with FOCAD
deletions. Truncating somatic mutations were identified
in none of three independent adenomas derived from
patient C or in a tumour sample derived from patient B.
These findings suggest haplo-insufficiency, rather than a
classical two-hit tumour suppressor gene scenario, to be
the most likely mechanism underlying CRC susceptibil-
ity in these patients.
Pathogenic FOCAD single nucleotide variants are
not enriched in polyposis/CRC patients
Since all identified deletions result in a loss of function
of FOCAD, we reasoned that pathogenic SNVs affect-
ing the function of its encoded protein (Focadhesin)
might also be enriched in early-onset or familial CRC
patients as compared to healthy controls. No nonsense,
frameshift or splice site mutations were identified in
a selected cohort of 117 early-onset/familial CRC
patients and 33 polyposis patients. We did, however,
identify three previously unreported missense variants,
p.Y759F, p.T1313A and p.S1660F (for all variants,
see supplementary material, Table S3), one of which
(p.S1660F) was predicted to be deleterious (see supple-
mentary material, Table S4). However, in order to draw
firm conclusions about its pathogenicity, additional
(functional) evidence has to be obtained. Moreover,
missense variants with similar in silico characteristics
have also been reported in healthy controls (see
supplementary material, Table S5).
Germline deletions of FOCAD are associated
with polyposis
To reveal whether FOCAD deletion-positive patients
share any phenotypic characteristics, the clinical data of
our patients and their family members were collected
and compared (Table 1). Patient A developed over 20
polyps and a rectal MSS carcinoma at the age of 33.
He had four relatives (second- and third-degree) with
CRC, but neither of his parents developed CRC (see
supplementary material, Figure S3). Co-segregation
analysis revealed that the same deletion was present in
the germline of his mother, who was not affected by
polyposis or CRC at time of last contact (age 66). Patient
B was diagnosed with CRC at age 62 years and, in addi-
tion, was found to have four relatives (first-, second-
and third-degree) diagnosed with CRC. Patient B
developed one traditional adenoma, her sister developed
three adenomas and two hyperplastic polyps and her
son was diagnosed with two hyperplastic polyps (see
supplementary material, Figure S3). Patient C also had a
positive family history for CRC, ie three relatives (first-
and second-degree) were affected (see supplementary
material, Figure S3). He was diagnosed with adenoma-
tous polyps at age 64 years and had a well-documented
history of constitutive polyp development for at least
7 years. Therefore, in addition to familial CRC, these
FOCAD deletion carriers appear to share a personal or
family history of polyposis.
FOCAD is expressed in epithelial cells of the colonic
crypt
Based on information available in public databases and
published data [23], FOCAD appears to be ubiqui-
tously expressed in almost all tissues, with the highest
levels in the brain and relatively low levels in colonic
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Figure 2. Diagram of germline FOCAD deletions, all affecting the ORF: the upper line schematically represents the FOCAD gene, its exons
(1–46) and the location of the miR-491 locus therein (intron 4); bars represent the deletions identified in each patient (A–C); deletions
(bars) and truncating mutations (arrowheads) depicted in grey have been encountered in an early-onset breast cancer (BC) and three
attenuated polyposis patients, respectively (see [32,33])
Table 1. Overview of clinical phenotypes of carriers of mono-allelic FOCAD deletions
Patient A B C
Gender Male Female Male
Age of onset (years) 33 62 64
CRC Yes Yes No
Polyposis >20 polyps Son and sister with polyps Constitutive polyp development
Number of relatives with CRC 4 4 3
FOCAD exons deleted 4–23 2–14 7–20
tissues, and localization of the encoded protein Focad-
hesin in the focal adhesion complex has been shown
[23]. To address the question of whether FOCAD may
execute a biologically relevant role within the colon, we
determined its expression level and pattern in normal
colonic tissue. Using real-time quantitative RT–PCR,
we indeed confirmed that the overall expression level of
FOCAD in colonic tissue is relatively low (Figure 3a).
Since normal colonic tissue contains several cell types
not directly associated with colonic tumourigenesis (eg
myofibroblasts, endothelial cells and non-pericryptal
fibroblasts), we set out to determine the expression of
FOCAD in human colonic organoids. Human colonic
organoids originate from crypt base columnar (CBC)
stem cells and form in vitro crypt–villus-like structures
without a mesenchymal niche and, therefore, only con-
tain epithelial cells known to be involved in CRC devel-
opment. We found that the expression level of FOCAD
is higher in organoids compared with normal colonic
samples (∼12-fold on average, normalized on HPRT)
(Figure 3b), which indicates that FOCAD is primarily
expressed in epithelial cells within the colon. By sub-
sequently employing RNA in situ hybridization (ISH),
we again found that FOCAD is expressed in the epithe-
lial cells within the colon (Figure 3c). Our findings show
that FOCAD is expressed in colonic epithelial cells that
may be involved in tumour formation and, therefore,
FOCAD may act as a tumour suppressor in polyposis
and CRC.
Variable expression of FOCAD in tumours
and tumouroids
To explore the expression pattern of FOCAD in CRC
samples, we initially compared the expression levels
of this gene in 12 matched normal and primary tumour
tissues, using quantitative RT–PCR. This analy-
sis revealed variable, but overall increased, levels
of FOCAD expression in the tumours (Figure 4a).
However, when expression levels were compared
between organoids and patient-matched tumouroids,
which are the tumourigenic equivalents of human
colonic organoids originating from adenocarcinoma
stem cells [30], no differences were observed. In fact,
some tumouroids even showed significantly reduced
expression of FOCAD compared to their matched
organoids (Figure 4b). Next, we applied RNA ISH to
multiple primary colonic tumour tissues and revealed
that the number of FOCAD-expressing cells differs
between different tumours (Figure 4c). This difference
in FOCAD-expressing cells may explain the observed
differences in FOCAD expression levels in tumour sam-
ples, and suggests an enrichment of a specific epithelial
cell subtype in some tumours. The exact nature of these
cells, however, still needs to be defined. Taken together,
our results show that cells expressing FOCAD are
present in most tumours and that, in accordance with
the absence of second-hit mutations, complete loss of
expression of FOCAD in colonic tumours is not likely
to be a common event in CRC development.
Discussion
Our data show that rare intragenic deletions in the
FOCAD gene recurrently occur in familial and early-
onset colorectal cancer (CRC) patients and that these
deletions are significantly enriched in patient cohorts
compared to unaffected control cohorts (p= 0.0067).
Furthermore, we noticed that germline FOCAD
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Figure 3. Expression of FOCAD in normal colonic tissue. (A) Relative average expression of FOCAD in normal colonic tissue normalized
to housekeeping gene HPRT (n= 12). (B) Expression levels of FOCAD in normal and organoid samples (average expression of 12 and 5
tissue samples, respectively). (C) RNA in situ hybridization reveals expression of FOCAD (red arrowheads) in epithelial cells within the colon;
magnifications= (left)× 10; (right)× 20
deletions may be associated with a polyposis phe-
notype, since multiple polyps were observed in all
affected individuals or their family members. This
observation is in agreement with a recent report in
which three individuals with attenuated polyposis were
described as carrying a deletion or truncating mutation
in FOCAD [32] (Figure 2). In addition, a constitu-
tional mono-allelic deletion in the FOCAD gene has
recently been reported in an early-onset breast cancer
patient [33], and recurrent deletions and somatic point
mutations in FOCAD have been observed in sporadic
cases of other cancer types [34–37] (Figure 2; see also
supplementary material, Figure S4). These somatic
and constitutional deletions in FOCAD substantiate its
putative role as a novel cancer (susceptibility) gene.
Polyposis/CRC susceptibility factors can be divided
into very rare variants with a high penetrance [38], inter-
mediate to rare variants with a moderate penetrance [16]
and common variants with a low penetrance [39]. Exten-
sive co-segregation analyses within the families reported
here could, unfortunately, not be performed, due to a
lack of material from the affected, often deceased, fam-
ily members. However, since this germline deletion was
also found to be present in a non-affected control and in
the non-affected mother of patient A, we conclude that
germline FOCAD deletions are not fully penetrant and
that additional germline variants may act as modifiers, as
has, for example, been reported previously for APC and
MLH1 [40,41]. Indeed, our patient with the earliest age
of onset (patient A, age 33 years) was found to harbour a
de novo pathogenic germline mutation in the exonucle-
ase domain of POLE (p.Leu424Val), which may explain
the early age of onset compared to the other polypo-
sis/CRC patients with a germline deletion in FOCAD.
Rare variants, such as FOCAD deletions with moderate
penetrances, may, however, still account for a significant
number of the unexplained hereditary polyposis/CRC
cases, which can now easily be identified through the
availability of efficient and robust detection methods
[28,42,43].
To further assess whether FOCAD may play a role
in polyposis and CRC development, we determined the
expression pattern of this gene in healthy colonic tissues,
including in vitro-cultured organoids. Based on infor-
mation available in public databases and published data
[23], FOCAD appears to be ubiquitously expressed in
almost all tissues, with the highest levels in brain. Here,
we show that FOCAD is expressed in epithelial cells
within the colon. Since normal colonic tissue contains
several non-epithelial cell types, the overall expression
of FOCAD is relatively low. This observation is in line
with the observed relatively high expression of FOCAD
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Figure 4. Expression of FOCAD in colonic carcinoma tissue. (A) Expression levels of FOCAD in normal and matched tumour samples (n= 12),
normalized to housekeeping gene HPRT . (B) Expression levels of FOCAD in organoid and patient-matched tumouroid (n= 5). (C) RNA in
situ hybridization for FOCAD in colonic tumour samples; (upper panels) large numbers of FOCAD-expressing epithelial cells are observed in
tumour sections (magnifications=×4 and× 10): (lower panels) microarray tumour sections show that the amounts of FOCAD-expressing
cells (red arrowheads) vary between colon tumours from different patients (four samples; magnification=×10). Tumours derived from
germline FOCAD deletion carriers could not be included in this analysis; **p< 0.01; n.s., not significant
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2015; 236: 155–164
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in organoids, which consist of only colonic epithelial
cells. The high expression levels of FOCAD in epithe-
lial cells within the colon is also in line with its potential
role as a novel polyposis/CRC susceptibility gene, since
aberrant proliferation of epithelial cells in colonic crypts
is considered to be an initiating step in the development
of polyposis/CRC.
All encountered deletions affect the ORF of FOCAD
and previously published data have shown that Focad-
hesin, the FOCAD-encoded protein, acts as a tumour
suppressor [23]. The observed germline deletions
strongly suggest a loss-of-function scenario, but somatic
second-hit mutations could not be identified in the
tumour and adenoma samples tested (from patients B
and C, respectively) and RNA ISH on sporadic colonic
tumours revealed that loss of FOCAD expression is not
a common event in colonic tumourigenesis. These find-
ings may point towards a haplo-insufficiency scenario.
On the other hand, complete loss of FOCAD expres-
sion due to homozygous FOCAD deletions has been
reported in glioblastomas [23] and breast cancers [36].
In addition, somatic second-hit mutations in FOCAD
were reported in an individual with attenuated polyposis
[32]. Together, these data suggest that FOCAD is a
tumour suppressor gene that can be subject to either
a classical two-hit or a haplo-insufficiency scenario.
In the epithelial cells of the colon, loss of one allele
of this gene may already underlie the development of
polyposis and CRC.
The lack of enrichment of deleterious germline SNVs
in the FOCAD gene in our CRC cohorts is remark-
able, since overall such variants are more frequent
in CRC-predisposing genes as compared to deletions
[42,44]. Protein truncating FOCAD variants are very
rare in the normal population, ie only two identical non-
sense variants were identified in our in-house exome
database (n= 2096) and truncating variants were only
observed in a small percentage of subjects (<0.07%)
listed in the ExAC database [45] (see supplementary
material, Figure S4). In contrast to our results, it has been
reported that targeted sequencing of 192 polyposis/CRC
patients revealed potentially truncating germline SNVs
in two attenuated polyposis patients [32]. We assume
that our strictly selected cohort was too small and/or
heterogeneous to reveal a significant enrichment of trun-
cating variants in the FOCAD gene.
Previously published data have shown that Focad-
hesin serves as a novel component of the focal adhesion
complex [23]. Although the exact function of Focad-
hesin remains to be established, components of the focal
adhesion complex, such as the focal adhesion kinase
(FAK), have already been linked to intestinal tumourige-
nesis [46]. Similar to the role of FAK in intestinal tumour
development, Focadhesin not only acts as a novel inter-
action partner for the focal adhesion complex but also
exerts crucial functions in cell survival and proliferation,
as illustrated by its negative effect on tumour growth
[23]. Thus, like other components of the focal adhesion
complex, a role of Focadhesin in the regulation of cell
proliferation and, therefore, tumourigenesis is assumed.
In conclusion, we show that FOCAD germline dele-
tions are recurrent and significantly enriched in patients
with a positive (familial) history of polyposis/CRC.
All identified deletions affect the ORF, suggesting a
loss-of-function scenario. The enhanced expression of
FOCAD in epithelial cells within colonic crypts sug-
gests a regulatory role of this gene in the proliferation of
potentially tumour-initiating colonic stem cells.We con-
clude that FOCADmay serve as a novel polyposis/CRC
susceptibility gene.
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